Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

NCT03514017 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Funding unavailable

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Pembrolizumab
DRUG: Ibrutinib

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]
[object Object]